Arcus Biosciences Chief Operating Officer Jennifer Jarrett Sells 27% Of Holding
Arcus Biosciences Chief Operating Officer Jennifer Jarrett Sells 27% Of Holding
We'd be surprised if Arcus Biosciences, Inc. (NYSE:RCUS) shareholders haven't noticed that the Chief Operating Officer, Jennifer Jarrett, recently sold US$241k worth of stock at US$17.92 per share. The eyebrow raising move amounted to a reduction of 27% in their holding.
如果Arcus Biosciences, Inc.(纽约证券交易所代码:RCUS)的股东没有注意到首席运营官詹妮弗·杰瑞特最近以每股17.92美元的价格出售了价值24.1万美元的股票,我们会感到惊讶。此次举措使他们的持股量减少了27%。
Arcus Biosciences Insider Transactions Over The Last Year
去年的Arcus Biosciences内幕交易
Notably, that recent sale by Chief Operating Officer Jennifer Jarrett was not the only time they sold Arcus Biosciences shares this year. Earlier in the year, they fetched US$19.35 per share in a -US$243k sale. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$17.24. So it is hard to draw any strong conclusion from it.
值得注意的是,首席运营官詹妮弗·贾瑞特最近的出售并不是他们今年唯一一次出售Arcus Biosciences的股票。今年早些时候,他们以-24.3万美元的销售额获得了每股19.35美元。虽然我们通常不喜欢看到内幕销售,但更令人担忧的是是否以较低的价格进行销售。好消息是,此次大宗销售远高于当前17.24美元的价格。因此,很难从中得出任何强有力的结论。
Jennifer Jarrett divested 26.01k shares over the last 12 months at an average price of US$18.61. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
詹妮弗·杰瑞特在过去12个月中以18.61美元的平均价格剥离了26.01万股股票。您可以看到下图所示的去年的内幕交易(公司和个人)。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240322/0-3e1f99ee9f65fc7570d088b5a831329b-0-db68e46e7627c777a5b1119df77ee997.png/big)
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。
Insider Ownership
内部所有权
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Arcus Biosciences insiders own about US$39m worth of shares. That equates to 2.4% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
测试公司领导者与其他股东之间一致性的另一种方法是查看他们拥有多少股份。通常,内部人士的所有权越高,内部人士长期建立公司的可能性就越大。Arcus Biosciences内部人士拥有价值约3900万美元的股票。这相当于该公司的2.4%。尽管这是一个强劲但并不突出的内部所有权水平,但这足以表明管理层与小型股东之间有一定的一致性。
So What Do The Arcus Biosciences Insider Transactions Indicate?
那么,Arcus Biosciences的内幕交易表明了什么呢?
An insider sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. So we'd only buy after careful consideration. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. For example - Arcus Biosciences has 3 warning signs we think you should be aware of.
一位内部人士最近出售了股票,但他们一直没有买入。在过去的一年里,没有任何能让我们感到安慰的购买。内部所有权并不是特别高,因此这种分析使我们对公司持谨慎态度。因此,我们只有在仔细考虑后才会购买。因此,虽然了解内部人士在买入或卖出方面的所作所为很有帮助,但了解特定公司面临的风险也很有帮助。例如,Arcus Biosciences有3个警告信号,我们认为你应该注意。
Of course Arcus Biosciences may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然,Arcus Biosciences可能不是最好的买入股票。因此,您可能希望看到这个免费的高质量公司集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。